Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)

Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes

(2013) Michael Horowitz et al.   ADVANCES IN THERAPY

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)

(2013) J. Rosenstock et al.   DIABETES CARE

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)

(2013) Bo Ahrén et al.   DIABETES CARE

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin

(2013) Matthew C. Riddle et al.   DIABETES CARE

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

(2013) Matthew C. Riddle et al.   DIABETES CARE

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)

(2013) M. Pinget et al.   DIABETES OBESITY & METABOLISM

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

(2013) C. Kapitza et al.   DIABETES OBESITY & METABOLISM

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia

(2013) Martin Lorenz et al.   REGULATORY PEPTIDES

Prevalence and trends of the diabetes epidemic in South Asia: a systematic review and meta-analysis

(2012) Ranil Jayawardena et al.   BMC PUBLIC HEALTH

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

(2012) V. A. Fonseca et al.   DIABETES CARE

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

(2012) Y. Seino et al.   DIABETES OBESITY & METABOLISM

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus

(2011) R. Keith Campbell   CLINICAL THERAPEUTICS

Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up: Lessons from the San Luigi Gonzaga Diabetes Study

(2011) F. Cavalot et al.   DIABETES CARE

Trends in the Prevalence of Type 2 Diabetes in Asians Versus Whites: Results from the United States National Health Interview Survey, 1997-2008

(2011) J. W. R. Lee et al.   DIABETES CARE

Globalization of Diabetes: The role of diet, lifestyle, and genes

(2011) F. B. Hu   DIABETES CARE

Managing diabetes in Asia: Overcoming obstacles and the role of DPP-IV inhibitors

(2011) Yi-Ming Mu et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia

(2011) Shih-Tzer TSAI et al.   Journal of Diabetes

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl

(2010) W. Yang et al.   DIABETES OBESITY & METABOLISM

Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring

(2010) J.-S. Wang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

(2010) R. E. Ratner et al.   DIABETIC MEDICINE

Impact of Race/Ethnicity on the Efficacy and Safety of Commonly Used Insulin Regimens: A Post Hoc Analysis of Clinical Trials in Type 2 Diabetes Mellitus

(2010) Jaime Davidson et al.   Endocrine Practice

The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes

(2010) D. Russell-Jones   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

(2010) Daisuke Yabe et al.   Journal of Diabetes Investigation

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

(2009) Sten Madsbad   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Postprandial Glucose - A Potential Therapeutic Target to Reduce Cardiovascular Mortality

(2009) Raj Peter et al.   Current Vascular Pharmacology

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

(2009) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Exenatide once weekly for the treatment of type 2 diabetes

(2009) James Malone et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Diabetes in Asia

(2009) Juliana C. N. Chan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

(2008) Yan Gao et al.   DIABETES RESEARCH AND CLINICAL PRACTICE